Abstract
Five courses of combination chemotherapy with methotrexate, cyclophosphamide and vincristine (MEV regimen) were given on an outpatient basis to sixteen previously untreated patients with lymphocytic lymphoma (L.L.) and to fourteen previously untreated patients with histiocytic lymphoma (H.L.) Clinical and haematological tolerance was such that the interval between each course was never prolonged, nor was drug dosage reduced (vincristine excepted). Of the 16 cases with L.L., there were 9 complete remissions, 5 of them being continuously unmaintained complete remissions for 5 to 24 months. Of the 14 cases with H.L., there were 13 complete remissions, 7 being continuously unmaintained complete remissions for 10 to 34 months. It is suggested that the combination of cell-cycle phase-specific drugs with an alkylating agent may prove to be more than additive in effect in non-Hodgkin's lymphoma. The very high remission rate in H.L. warrants further investigation.
| Original language | English |
|---|---|
| Pages (from-to) | 343-349 |
| Number of pages | 7 |
| Journal | European Journal of Cancer (1965) |
| Volume | 11 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1975 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin's lymphoma. / Lauria, Francesco; Baccarani, Michele; Fiacchini, Mauro; Gobbi, Marco; Tura, Sante.
In: European Journal of Cancer (1965), Vol. 11, No. 5, 1975, p. 343-349.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin's lymphoma
AU - Lauria, Francesco
AU - Baccarani, Michele
AU - Fiacchini, Mauro
AU - Gobbi, Marco
AU - Tura, Sante
PY - 1975
Y1 - 1975
N2 - Five courses of combination chemotherapy with methotrexate, cyclophosphamide and vincristine (MEV regimen) were given on an outpatient basis to sixteen previously untreated patients with lymphocytic lymphoma (L.L.) and to fourteen previously untreated patients with histiocytic lymphoma (H.L.) Clinical and haematological tolerance was such that the interval between each course was never prolonged, nor was drug dosage reduced (vincristine excepted). Of the 16 cases with L.L., there were 9 complete remissions, 5 of them being continuously unmaintained complete remissions for 5 to 24 months. Of the 14 cases with H.L., there were 13 complete remissions, 7 being continuously unmaintained complete remissions for 10 to 34 months. It is suggested that the combination of cell-cycle phase-specific drugs with an alkylating agent may prove to be more than additive in effect in non-Hodgkin's lymphoma. The very high remission rate in H.L. warrants further investigation.
AB - Five courses of combination chemotherapy with methotrexate, cyclophosphamide and vincristine (MEV regimen) were given on an outpatient basis to sixteen previously untreated patients with lymphocytic lymphoma (L.L.) and to fourteen previously untreated patients with histiocytic lymphoma (H.L.) Clinical and haematological tolerance was such that the interval between each course was never prolonged, nor was drug dosage reduced (vincristine excepted). Of the 16 cases with L.L., there were 9 complete remissions, 5 of them being continuously unmaintained complete remissions for 5 to 24 months. Of the 14 cases with H.L., there were 13 complete remissions, 7 being continuously unmaintained complete remissions for 10 to 34 months. It is suggested that the combination of cell-cycle phase-specific drugs with an alkylating agent may prove to be more than additive in effect in non-Hodgkin's lymphoma. The very high remission rate in H.L. warrants further investigation.
UR - http://www.scopus.com/inward/record.url?scp=0016684984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016684984&partnerID=8YFLogxK
U2 - 10.1016/0014-2964(75)90062-6
DO - 10.1016/0014-2964(75)90062-6
M3 - Article
C2 - 1098915
AN - SCOPUS:0016684984
VL - 11
SP - 343
EP - 349
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0014-2964
IS - 5
ER -